Tailong Pharmaceutical (600222.SH) disclosed its 2023 annual report, and the company achieved revenue of 20 in 2023...
According to Zhitong Finance App News, Tailong Pharmaceutical (600222.SH) disclosed its 2023 annual report. The company achieved revenue of 2.07 billion yuan in 2023, an increase of 5.57% over the previous year; net profit to mother of 43.56 million yuan, turning a year-on-year loss into a profit; deducting non-net profit of 34.6 million yuan, turning a year-on-year loss into a profit; and basic earnings per share of 0.0774 yuan.
During the reporting period, with the stabilization of the external environment, the company's business grew steadily and continued to improve, and revenue increased 5.57% year on year. In particular, the company's traditional Chinese medicine oral liquid business achieved a 26.47% increase in revenue by strengthening market expansion, enriching the product matrix, and optimizing the product structure. At the same time, it continued to strengthen cost control in various business sectors and promote cost reduction and efficiency measures, driving the company's overall gross profit and net profit to a significant increase.